Clinical and experimental dermatology · 2026
Clinicodemographic characteristics of pemphigus foliaceus: retrospective analysis of clinic-based data for 103 patients in a nonendemic location.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
De Dipankar, Sharma Apoorva, Hanumanthu Vinod, Chatterjee Debajyoti, Saikia Uma Nahar, Saikia Biman, Mahajan Rahul, Handa Sanjeev
Аннотация
BACKGROUND: Pemphigus foliaceus (PF) is an uncommon autoimmune disease characterized by superficial blistering and erosions of the skin. The literature on PF globally is limited. Understanding clinicodemographic heterogeneity in PF is crucial for improving outcomes for affected individuals.
OBJECTIVES: To study the clinicodemographic characteristics and treatment outcomes of patients with PF in north India.
METHODS: A retrospective study was conducted of patients with PF registered at the authors' clinic at the Postgraduate Institute of Medical Education and Research in Chandigarh, north India, between November 2013 and June 2023.
RESULTS: In total, 103 patients with PF were included in the study. The mean (SD) age at disease onset was 40.4 (15.7) years, with a male-to-female ratio of 1.7 : 1. The median duration of disease at presentation was 18 months (range 1-240). The most commonly prescribed treatment was topical corticosteroids (n = 98/103; 95.1%) or oral corticosteroids (n = 97/103; 94.2%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant and was used in 43.7% (n = 45/103) of patients. Overall, 75.7% (n = 78/103) of patients achieved clinical remission on minimal treatment (CRmin) in a mean of 6.5 (3.9) months. Clinical remission off treatment (CRoff) was achieved in 10.4 (6.0) months in 67.0% (n = 69/103) of patients. Among patients in the rituximab group, CRmin was achieved in 91.1% (n = 41/45) of patients in 6.3 (4.6) months and CRoff was achieved in 82.2% (n = 37/45) of patients in 9.0 (5.6) months.
CONCLUSIONS: In the present study PF was more common in men aged between 40 and 60 years. Corticosteroids (topical/systemic) formed the mainstay of treatment, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required for a better understanding of this disease in nonendemic locations.
OBJECTIVES: To study the clinicodemographic characteristics and treatment outcomes of patients with PF in north India.
METHODS: A retrospective study was conducted of patients with PF registered at the authors' clinic at the Postgraduate Institute of Medical Education and Research in Chandigarh, north India, between November 2013 and June 2023.
RESULTS: In total, 103 patients with PF were included in the study. The mean (SD) age at disease onset was 40.4 (15.7) years, with a male-to-female ratio of 1.7 : 1. The median duration of disease at presentation was 18 months (range 1-240). The most commonly prescribed treatment was topical corticosteroids (n = 98/103; 95.1%) or oral corticosteroids (n = 97/103; 94.2%), either alone or in combination with steroid-sparing adjuvants. Rituximab was the commonest adjuvant and was used in 43.7% (n = 45/103) of patients. Overall, 75.7% (n = 78/103) of patients achieved clinical remission on minimal treatment (CRmin) in a mean of 6.5 (3.9) months. Clinical remission off treatment (CRoff) was achieved in 10.4 (6.0) months in 67.0% (n = 69/103) of patients. Among patients in the rituximab group, CRmin was achieved in 91.1% (n = 41/45) of patients in 6.3 (4.6) months and CRoff was achieved in 82.2% (n = 37/45) of patients in 9.0 (5.6) months.
CONCLUSIONS: In the present study PF was more common in men aged between 40 and 60 years. Corticosteroids (topical/systemic) formed the mainstay of treatment, with rituximab being the most commonly used steroid-sparing adjuvant. Prospective studies in a larger cohort are required for a better understanding of this disease in nonendemic locations.